Cellular and Clinical Impact of Haploinsufficiency for Genes Involved in ATR Signaling  by O’Driscoll, Mark et al.
www.ajhg.org The American Journal of Human Genetics Volume 81 July 2007 77
ARTICLE
Cellular and Clinical Impact of Haploinsufficiency for Genes
Involved in ATR Signaling
Mark O’Driscoll, William B. Dobyns, Johanna M. van Hagen, and Penny A. Jeggo
Ataxia telangiectasia and Rad3-related (ATR) protein, a kinase that regulates a DNA damage–response pathway, is mutated
in ATR-Seckel syndrome (ATR-SS), a disorder characterized by severe microcephaly and growth delay. Impaired ATR
signaling is also observed in cell lines from additional disorders characterized by microcephaly and growth delay, including
non–ATR-SS, Nijmegen breakage syndrome, and MCPH1 (microcephaly, primary autosomal recessive, 1)–dependent pri-
mary microcephaly. Here, we examined ATR-pathway function in cell lines from three haploinsufficient contiguous gene-
deletion disorders—a subset of blepharophimosis-ptosis-epicanthus inversus syndrome, Miller-Dieker lissencephaly syn-
drome, and Williams-Beuren syndrome—in which the deleted region encompasses ATR, RPA1, and RFC2, respectively.
These three genes function in ATR signaling. Cell lines from these disorders displayed an impaired ATR-dependent DNA
damage response. Thus, we describe ATR signaling as a pathway unusually sensitive to haploinsufficiency and identify
three further human disorders displaying a defective ATR-dependent DNA damage response. The striking correlation of
ATR-pathway dysfunction with the presence of microcephaly and growth delay strongly suggests a causal relationship.
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Ataxia telangiectasia and Rad3-related (ATR) protein is a
central component of a DNA damage–response signaling
pathway.1,2 ATR (MIM *601215) is mutated in two families
displaying Seckel syndrome (SS) (MIM #210600), a dis-
order characterized by severe microcephaly, proportionate
dwarfism, and dysmorphic facial features.3–5 SS is clinically
and genetically heterogeneous.6 Significantly, cell lines de-
rived from additional patients with SS, although not har-
boring mutations in ATR, display ATR-signaling defects.6
Thus, SS can be attributed to defects in ATR signaling, with
a subset of patients, designated “ATR-SS,” having muta-
tions in ATR itself. Additionally, three other disorders char-
acterized by microcephaly and growth delay—Nijmegen
breakage syndrome (MIM #251260), Fanconi anemia (MIM
#227650), and MCPH1 (microcephaly, primary autoso-
mal recessive, 1)–defective primary microcephaly (MIM
#251200)—display impaired ATR-signaling responses.7,8 To-
gether, these findings suggest that impaired ATR signaling
can impact development, conferring microcephaly and
growth delay.
ATR is a phosphoinositol 3-kinase–like kinase (PIKK) that
is activated by single-stranded (ss) regions of DNA gen-
erated after replication-fork stalling or during the repair
of bulky lesions.9 ATR interacts with ATRIP (ATR-interact-
ing protein) and is recruited to ssDNA regions, in part by
ATRIP’s ability to bind to replication protein A (RPA), a
complex of three subunits, RPA1–3.9–11 The Rad17/Rfc2–5
complex, together with a complex involving Rad9, Rad1,
and Hus1, also functions to enhance ATR signaling, by
impacting either ATR recruitment or activation.12 Thus,
these additional proteins are required for the ATR-signal-
ing response and therefore represent potential candidate
genetic defects for SS.6 Hence, defects in these genes may
confer “Seckel-like” clinical features.
High-resolution genetic mapping studies have led to
the characterization of contiguous-gene-deletion disor-
ders caused by heterozygous microdeletions that result in
haploinsufficiency for a single or, more usually, several
genes.13,14 It is likely that the clinical manifestations of
these disorders arise from the combined impact of hap-
loinsufficiency for multiple genes.15 It is also possible that
there are critical genes or pathways sensitive to haploin-
sufficiency, either alone or when combined with haploin-
sufficiency for other genes. While investigating disorders
exhibiting microcephaly and growth delay, we were struck
by the observation that the microdeletion in three such
disorders involved haploinsufficiency for genes involved
in ATR-pathway function.
Blepharophimosis-ptosis-epicanthus inversus syndrome
(BPES [MIM #110100]), which is characterized by small
eye sockets (blepharophimosis), drooping eyelids (ptosis),
and upward-folding inner eyelids (epicanthus inversus), is
an autosomal dominant disorder caused by mutation of
the putative forkhead transcription factor FOXL2 (MIM
*605597).16,17 Seventeen cases of BPES with heterozygous
interstitial deletions of various sizes on chromosome 3q
leading to loss of FOXL2 have been documented (reviewed
by de Rue et al.18). Of these, 13 patients were also reported
to exhibit microcephaly and growth retardation, clinical
features not normally associated with BPES. Recently, the
microdeletion in one such patient was carefully mapped
and was shown to encompass ATR, which localizes to the
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same region.18 It was therefore proposed that the non-BPES
features observed in such patients might be due to hap-
loinsufficiency for ATR.18
Hemizygous deletions on chromosome 17p also confer
microcephaly and growth delay.19 PAHFAH1B1/Lis1 (MIM
*601545) encodes a protein, lissencephaly 1 (Lis1) that
functions in neuronal migration.20 Mutations in or het-
erozygous deletions of PAHFAH1B1/Lis1 alone cause iso-
lated lissencephaly sequence (ILS), a disorder typified by
reduced neuronal migration resulting in a “smooth brain”
(lissencephaly).21 Larger deletions identified in some pa-
tients with ILS confer a more severe grade of lissencephaly
associated with craniofacial abnormalities (ILS). Even
larger deletions extending from the PAHFAH1B1/Lis1 gene
to the telomere are observed in Miller-Dieker lissenceph-
aly syndrome (MDLS [MIM #247200]), a disorder charac-
terized by the most severe grade of lissencephaly, with
craniofacial abnormalities, microcephaly, and growth re-
tardation. RPA1 (MIM *179835), the largest subunit of
RPA, is heterozygously deleted in patients with MDLS and
ILS but not ILS.19
Finally, Williams-Beuren syndrome (WBS [MIM
#194050]) is caused by hemizygous deletion of chromo-
some 7q11.23, which results in the haploinsufficiency of
multiple genes.22 WBS is characterized by facial dysmor-
phia, microcephaly, growth retardation, and supravalvular
aortic stenosis (SVAS [MIM #185500]). Hemizygous dele-
tion or mutations in ELN (MIM *130160) alone, the gene
encoding elastin, a structural component of arteries, cause
SVAS.23 Patients with WBS, in contrast, have larger dele-
tions encompassing replication factor C2 (RFC2 [MIM
*600404]), a subunit of replication factor C (RF-C).24 RF-
C loads proliferating cell nuclear antigen (PCNA) onto
chromatin during DNA replication, and four of its five
subunits, Rfc2–5, form a complex with Rad17 that func-
tions in ATR signaling.11,25–27
The association of severe microcephaly and growth re-
tardation with heterozygous loss of genes encoding pro-
teins involved in the ATR-signaling pathway prompted us
to examine whether haploinsufficiency for these genes im-
pacts the ATR-signaling response. We therefore examined
cell lines obtained from these contiguous gene disorders
for their ability to effect the ATR-dependent DNA-damage
response. We employed sensitive assays capable of detect-
ing defective ATR-pathway function that we had established
elsewhere to examine SS cell lines. Strikingly, we observed
defects in ATR signaling in all three disorders, demonstrat-
ing that ATR signaling is sensitive to haploinsufficiency.
Material and Methods
Cell Lines
Lymphoblastoid cell lines (LBLs) were cultured in RPMI 1640 with
15% fetal calf serum. GM02188 (wild type [WT]) and DK0064
(ATR-SS) have been described elsewhere.6 VD9396 (BPES-ATR/)
LBLs were obtained from J.M.v.H.18 ILS, ILS, and MDLS LBLs—
DR00-063a1 (Con-MR), LP99-017 (ILS A), LP94-013 (ILS B), LP90-
017 (ILS A), LP99-086 (ILS B), LP91-026 (ILS C), L95-059
(MDLS-A), LP92-005 (MDLS-B), LP90-006 (MDLS-C), and LP88-
002 (MDLS-D)—have been described elsewhere and were pro-
vided by W.B.D.19 WBS and respective parental LBLs—GM14183
(WT-I), GM14182 (WBS-I), GM14295 (WT-II), and GM14297
(WBS-II)—were obtained from Coriell Cell Repository.
Antibodies
Antibodies were obtained as follows. a-ATR (N19), a-Lis1 (H-300),
and a-b-tubulin (H235) were obtained from Autogen Bioclear;
a-RPA1 (Ab-1), a-H2AX (DR-1016), and a-NBS1 (Ab-1) were ob-
tained from Merck; a–g-H2AX, a-pS10 Histone H3, and a-ATRIP
were obtained from Upstate Technology; and a-pSer317-Chk1
was obtained from New England Biolabs.
Western Blotting and Chromatin Extraction
Western blotting was performed as described elsewhere.8 For g-
H2AX analysis, a chromatin extraction step was included. In brief,
cells were washed once in PBS and were resuspended in71# 10
100 ml hypotonic buffer (10 mM HEPES [pH 7.5], 5 mM KCl, 1.5
mM MgCl2, 1 mM dithiothreitol, 10 mM NaF, 1 mM Na2VO3, 10
mM b-glycerolphosphate, 0.5% IPEGAL/Nonident P-40, and Pro-
tease Inhibitor Cocktail from Sigma). Lysates were incubated on
ice for 15 min, were pelleted, and were washed twice (200 ml each)
in hypotonic buffer. The pellet was treated with hypertonic buffer
(hypotonic buffer with 0.5 M NaCl) and was incubated on ice for
15 min. After washing in hypertonic buffer, the chromatin pellets
were resuspended in 100 ml of SDS-PAGE loading buffer (with 5%
SDS, 10% b-mercaptoethanol) and were sonicated. Ten microliters
of the chromatin fraction was separated on 17% SDS-PAGE.
G2/M Checkpoint Arrest
Cells were irradiated with 5 J/m2 UV-C, were immediately seeded
into complete medium with 1.5 mM nocodazole, and were incu-
bated for 24 h before being cytospun onto poly-D-lysine–coated
slides and processed for immunofluorescence with a-pS10-Histone
H3 and for counterstaining with 4’,6-diamidino-2-phenylindole.
Nuclear Fragmentation (NF)
Cells were treated with 5 mM hydroxyurea (HU) in the presence
of 1.5 mM nocodazole for 24 h and were processed as described
elsewhere.6
Transfection
With use of Genejuice (Novagen), cells/ml, in 3-ml quan-53# 10
tities, were transiently transfected with 2 mg of pcDNA3-ATR,
pcDNA3.1-RPA1, or pcDNA3.1-RFC2, according to the manufac-
turer’s instructions, and were incubated for 24 h before NF pro-
cessing. For complementation of the G2/M checkpoint, cells were
incubated for 24 h and were retransfected for a further 24 h before
processing.
RNA-Interference Transfection
The control WT LBL GM02188 was used for small-interfering RNA
(siRNA) experiments. Cells were transfected once with 10 nM of
respective siRNA duplex (GFPi, ATRi, Lis1i, or RPA1i), with use
of SiPort NeoFX transfection reagent according to the manufac-
turer’s instructions (Ambion). The oligonucleotides (sense) used
were ATR 5′-AAC CUC CGU GAU GUU GCU UGA-3′, RPA1 5′-
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Figure 1. BPES-ATR/ cells, which display an impaired ATR-dependent damage response. A, Chromosome 3 karyotype of the patient
with BPES-ATR/ showing the heterozygous deletion, del(3)(q23,q25). ATR localizes to 3q22-q24. Cenpcentromere; Telptelomere.
B, WCE (100 mg) from WT and BPES-ATR/ LBLs, analyzed by immunoblotting using a-ATR, ATRIP, and NBS1 antibodies. Reduced
expression of ATR and ATRIP is seen in BPES-ATR/ cells specifically. NBS1 served as a loading control and was expressed at normal
levels. C, WT, ATR-SS, and BPES-ATR/ LBLs, exposed to 100 or 500 mM HU for 1 h before chromatin fractionation. ATR-SS and BPES-
ATR/ cells display reduced g-H2AX compared with WT cells. Blots were reprobed using a-H2AX to confirm loading. D, WT, ATR-SS,
and BPES-ATR/ LBLs, exposed to 500 mM HU for 1 h before extraction. ATR-SS and BPES-ATR/ cells display reduced Chk1-pS317
formation compared with WT cells. Blots were reprobed using a-Chk1 to confirm loading. E, ATR-SS and BPES-ATR/ LBLs showing
defective UV-induced (5 J/m2) G2/M checkpoint arrest 24 h postirradiation. Arrest in WT LBLs is seen as a decrease in the MI after UV
irradiation. F, ATR-SS and BPES-ATR/ LBLs that, unlike WT cells, show increased NF after 24 h treatment with HU (5 mM). G, UV-
induced G2/M defect in BPES-ATR/ LBLs, complemented after transfection with ATR cDNA. BPES-ATR/ cells, either untransfected
(UNT) or transfected (ATR) with pc-DNA3-ATR, were UV irradiated (5 J/m2), and the MI was determined after 24 h. H, HU-induced NF
in BPES-ATR/, complemented after transfection with ATR cDNA. BPES-ATR/ LBLs either untransfected (UNT) or transfected (ATR)
with pc-DNA3-ATR were untreated (Conpcontrol) or treated with HU (5 mM) 24 h posttransfection. NF was analyzed 24 h posttreatment
with HU.
AAA CCA UCC ACG AAG CUU AUA GGC C-3′, Lis1 5′-UUG AUU
UGG CCG UAC CAU ACG UAC C-3′, and a control oligonucleo-
tide directed to GFP 5′-AAC ACU UGU CAC UAC UUU CTC.
Results
ATR Signaling Impaired in a BPES Cell Line
Haploinsufficient for ATR
A previous study reported heterozygosity for ATR due to
an interstitial deletion on 3q in a boy with BPES who
displayed non-BPES clinical features that included mental
retardation (MR), microcephaly, and growth delay.18 A rep-
resentation of the deletion is shown in figure 1A. We ob-
tained an LBL derived from this patient (BPES-ATR/)
and, by immunoblotting, observed approximately twofold
reduced ATR protein levels compared with those of a con-
trol LBL (fig. 1B). The level of ATRIP was also reduced ap-
proximately twofold, consistent with reports that ATR and
ATRIP are coregulated.10 NBS1 served as a loading control
and was expressed at similar levels in both lines (fig. 1B).
An early step in the DNA damage response regulated by
ATR is phosphorylation of the histone H2A variant, H2AX,
on serine 139 (termed “g-H2AX”), which can be detected
by the immunoblotting of chromatin-bound proteins with
a–g-H2AX antibodies.28 After exposure to HU, an agent
that causes replication-fork stalling, a strong g-H2AX sig-
nal was observed in control LBLs, indicating activation of
ATR-dependent damage-response signaling. However, in
marked contrast, detectable g-H2AX was not observed in
the ATR-SS LBLs, nor in LBLs derived from the patient
with BPES-ATR/ (fig. 1C). Chk1 represents an impor-
tant phosphorylation target of ATR that is required for
the stability of arrested replication forks and cell-cycle ar-
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Figure 2. MDLS cells, which display an impaired ATR-dependent DNA damage response. A, Chromosome 17 karyotype of MDLS high-
lighting the heterozygous deletion at 17p13.3. B, Deletion mapping in the panel of LBLs from patients with ILS, ILS, and MDLS. The
dashed line indicates the heterozygously deleted region. Con-MR is a control LBL from a patient with mild MR who does not exhibit
lissencephaly, microcephaly, growth retardation, or MDLS but has a hemizygous telomeric deletion that does not involve either RPA1
or PAFAH1B1/Lis1. ILS A and ILS B denote patients with low-grade ILS due to microdeletions involving PAFAH1B1/Lis1 only. ILSA,
ILSB, and ILSC denote patients with larger deletions, a more severe ILS, and additional craniofacial abnormalities, whereas MDLS-
A, -B, -C, and -D denote patients with the largest deletions, who exhibit the most severe grade of lissencephaly along with microcephaly
and growth retardation. The positions of PAFAH1B1/Lis1 and RPA1 are highlighted. C, Western-blot analysis of RPA1 expression from
WCEs from Con-MR, ILS A, ILS B, MDLS-A, MDLS-B, and MDLS-C showing reduced expression of RPA1, specifically in the three MDLS cell
lines. D, Defective HU-induced g-H2AX formation, which segregates with RPA1 haploinsufficiency. Cells were treated as described for
figure 1C. Defective g-H2AX formation is seen in ATR-SS, ILS A, and MDLS-A cells, compared with the normal response in WT, Con-
MR, ILS A, and ILS B cells. E, Impaired HU-induced Chk1-pS317, seen in MDLSA LBLs, compared with those of Con-MR and ILS A. Cells
were treated with 500 mM HU for 1 h before extraction and were reprobed using a-Chk1 to confirm loading.
rest.29–33 HU-induced phosphorylation of Chk1 on serine
317, a known ATR target site, was also significantly di-
minished in LBLs from the patient with BPES-ATR/,
similar to ATR-SS LBLs (fig. 1D).6 An important end point
of ATR activation regulated by Chk1 is onset of G2/M
checkpoint arrest, which serves to prevent cells harboring
DNA damage from entering mitosis.6 To monitor G2/M
checkpoint arrest, the percentage of mitotic cells was ex-
amined in untreated cells or 24 h postirradiation with UV
(5 Jm2). Control LBLs showed a marked reduction in mi-
totic cells due to arrest at the G2/M checkpoint, whereas
ATR-SS and BPES-ATR/ cells showed a mitotic index
(MI) similar to that observed in the absence of UV treat-
ment (fig. 1E). A further hallmark of impaired ATR sig-
naling is the presence of cells with NF after treatment with
HU.6 ATR-SS and BPES-ATR/ LBLs showed markedly
elevated levels of cells displaying NF after HU treatment,
in contrast to those of control LBLs (fig. 1F). To verify that
the failure to effect G2/M checkpoint arrest and that the
damage-induced NF phenotype of BPES-ATR/ cells were
directly attributable to an impaired ATR response, the cells
were transfected with ATR cDNA and were reexamined for
these phenotypes. Significant UV-induced G2/M arrest (fig.
1G) and reduced NF (fig. 1H) were observed after trans-
fection with ATR cDNA.
Collectively, these results provide strong evidence that
haploinsufficiency for ATR in the BPES-ATR/ cell line
confers an impaired response to DNA damage that is sim-
ilar in magnitude to that observed in an ATR-SS cell line.
Cells Haploinsufficient for RPA1 Show Deficient
ATR-Dependent DNA Damage–Response Signaling
A representation of the deletion on chromosome 17p ob-
served in MDLS is shown in figure 2A. The size of the
heterozygous deletions on chromosome 17p in a panel of
LBLs derived from patients with ILS, ILS, and MDLS and
from a control patient (Con-MR) are shown in figure 2B.
ILS A and ILS B were derived from patients with mild ILS
due to microdeletions involving Lis1 only. ILS A, ILS
B, and ILS C were obtained from patients with more-
severe ILS and craniofacial abnormalities. MDLS-A, -B, -C,
and -D, which have deletions extending from Lis1 to the
telomere, were derived from MDLS-affected patients with
the severest grade of lissencephaly together with micro-
cephaly and growth retardation. Con-MR, which has a
heterozygous telomeric deletion that does not involve ei-
ther RPA1 or Lis1, was derived from a patient with mild
MR (fig. 2B). This patient does not exhibit MDLS, lissen-
cephaly, microcephaly, or growth delay. The location of
RPA1 is shown in figure 2B, demonstrating that this gene
is deleted in some but not all LBLs in the panel. To exam-
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Figure 3. Haploinsufficiency of RPA1, which specifically segregates with a defective ATR-dependent DNA damage response. A, Defective
ATR-dependent G2/M checkpoint arrest, which segregates with RPA1 haploinsufficiency. Con-MR, ILS A, and ILS B cells showing a
reduction in MI (percentage of mitosis) at 24 h after UV irradiation (5 J/m2), indicating G2/M checkpoint arrest. ILS A, ILS B,
ILS C, and MDLS-A, -B, -C, and -D cell lines failed to show a decrease in MI after UV treatment. B, Increased HU-induced NF segregating
with RPA1 haploinsufficiency. No increase in HU-induced NF is seen in Con-MR, ILS A, or ILS B cells. In contrast, ILS A, ILS B,
ILS C, and MDLS-A, -B, -C, and -D cells show elevated HU-induced NF. C, The ATR-dependent UV-induced G2/M defect in MDLS cells,
complemented after transfection with RPA1 cDNA. MDLS-A and MDLS-C cells, either untransfected (“UNT”) or transfected (“RPA1”) with
pc-DNA3-RPA1, were unirradiated (Conpcontrol) or UV-irradiated (“UV”) (5 J/m2), and the MI was determined after 24 h. RPA1 cDNA
specifically corrected the G2/M checkpoint defect of these cells, as seen by the reduced UV-induced MI after transfection (“RPA1 UV”),
compared with untransfected irradiated cells (“UNT UV”). D, The increased HU-induced NF seen in MDLS, complemented after transfection
with RPA1 cDNA. MDLS-A and -C, either untransfected (“UNT”), or transfected (“RPA1”) with pc-DNA3-RPA1 were untreated (“Con”) or
treated with HU (5 mM) 24 h posttransfection. A reduction in HU-induced NF is specifically seen after transfection of MDLS LBLs with
RPA1 cDNA (“RPA1 HU”), compared with the untransfected (“UNT HU”) cells.
ine whether haploinsufficiency for RPA1 correlated with
impaired ATR-dependent damage-response signaling, we
examined the response to DNA damage in this panel of
LBLs. First, we examined RPA1 expression in whole-cell
extracts (WCEs) derived from Con-MR, ILS A, and ILS B,
compared with MDLS-A, -B, and -C. All three MDLS LBLs
displayed reduced levels of RPA1 compared with those of
Con-MR, ILS A, and ILS B LBLs, which is consistent with
the deletion mapping (fig. 2B). Next, we examined HU-
induced g-H2AX formation in representative LBLs, either
haploinsufficient for RPA1 or with both copies of the gene.
Impaired HU-induced g-H2AX was observed in the ATR-
SS, ILS A, and MDLS A LBLs, the latter two of which
exhibit haploinsufficiency for RPA1 (fig. 2B and 2D). Nor-
mal HU-induced g-H2AX was observed in WT control
LBLs and in those cell lines in which the deletion did not
encompass RPA1 (Con-MR, ILS A, and ILS B) (fig. 2B and
2D). Similarly, MDLS-A LBLs also exhibited impaired HU-
induced Chk1-pSer317 formation, unlike Con-MR and ILS
A LBLs (fig. 2E). We also examined the ability to activate
UV-induced G2/M checkpoint arrest and observed im-
paired arrest specifically in the seven LBLs with haploin-
sufficiency for RPA1 (figs. 2B and 3A). Furthermore, we
examined HU-induced NF and observed elevated levels
specifically in those LBLs from patients haploinsufficient
for RPA1 (figs. 2B and 3B).
To verify that the G2/M checkpoint and NF phenotypes
were a consequence of haploinsufficiency for RPA1, these
damage-response phenotypes were examined after trans-
fection of two MDLS LBLs (MDLS-A and MDLS-C) with
RPA1 cDNA. Expression of RPA1 cDNA resulted in recovery
of G2/M checkpoint arrest and a diminished number of
cells displaying HU-induced NF in both LBLs (fig. 3C and
3D).
Mildly Decreased Expression of RPA1 and ATR but Not Lis1
with Use of siRNA Affects ATR-Pathway Function after DNA
Damage
As an alternative way to determine whether the ATR-de-
pendent DNA damage response might be sensitive to small
perturbations in ATR or RPA1 expression, we used a single
round of transfection with a low concentration (10 nM)
of siRNA oligonucleotides to mildly reduce the expression
of Lis1, RPA1, and ATR in the control LBLs. We obtained
an approximately twofold reduction in Lis1, RPA1, and
ATR expression in control LBLs (fig. 4A). This reduction
in RPA1 and ATR protein levels conferred a failure to ac-
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Figure 4. Inefficient siRNA of ATR or RPA1, which impairs the ATR-dependent DNA damage response. A, WT LBLs transfected once
with a low concentration (10 nM) of siRNA oligonucleotides for GFP, Lis1, RPA1, or ATR and analyzed for expression of Lis1, RPA1, and
ATR by western blotting, using b-tubulin as a loading control, 24 h posttransfection. B, WT LBLs untransfected (UNT) or transfected
with the indicated siRNA oligonucleotides, analyzed for UV-induced G2/M checkpoint arrest by monitoring MI. Transfection with siRNA
oligonucleotides against ATR or RPA1 impaired G2/M arrest after UV. In contrast, after transfection with oligonucleotides against GFP
and Lis1, an intact G2/M arrest was observed. C, WT LBLs transfected with the indicated siRNA oligonucleotides, analyzed for HU-
induced NF. Transfection with siRNA oligonucleotides against ATR and RPA1 caused HU-induced NF, in contrast to the lack of impact
of siRNA oligonucleotides against GFP and Lis1.
tivate G2/M checkpoint arrest after UV irradiation (fig.
4B). In contrast, the clearly observable reduction in Lis1
expression after siRNA did not impact UV-induced G2/M
checkpoint arrest (fig. 4B). Similarly, mild siRNA-mediated
reduction in the expression of ATR and RPA1 caused ele-
vated levels of NF after HU treatment, which was not ob-
served after siRNA with use of oligonucleotides directed
against Lis1 or GFP (fig. 4C).
These results provide strong evidence suggesting that
even a mild decrease in protein levels of either ATR or
RPA1 impacts the ability of cells to mount a normal ATR-
signaling response after exposure to DNA damage.
Impaired ATR-Dependent DNA Damage–Response Signaling
in WBS: Correlation with Haploinsufficiency for RFC2
The heterozygous interstitial deletion on chromosome
7q11.23 that is seen in WBS is shown in figure 5A. The
deletion encompasses multiple genes, including RFC2, a
subunit of the Rad17/Rfc2-5 complex that plays a role in
the ATR-dependent pathway (fig. 5B). Figure 5B also shows
the microdeletion observed in a typical patient with SVAS
that does not encompass RFC2 but includes ELN. Whereas
a hypomorphic mutation in Saccharomyces cerevisiae RFC2
(rfc2-1) has been shown to impair normal cell-cycle check-
point activation, a direct demonstration of a similar re-
sponse in humans cells has not been described.34 To ex-
amine whether haploinsufficiency for RFC2 causes im-
paired ATR-dependent damage response, we examined
two WBS LBLs (WBS-I and WBS-II) and LBLs derived from
one clinically normal parent (WT-I and WT-II, respective-
ly). Significantly, defective HU-induced Chk1-pS317 for-
mation was also seen in WBS LBLs (WBS-I and WBS-II),
compared with their clinically normal parental LBLs (WT-
I and WT-II, respectively) (fig. 5C). Correspondingly, both
WBS LBLs failed to induce any significant G2/M check-
point arrest after exposure to UV, in contrast to the effi-
cient checkpoint arrest observed in both parent lines (fig.
5D). Additionally, both WBS LBLs but neither parental line
showed induction of NF after exposure to HU (fig. 5E).
Elevated levels of G2/M checkpoint arrest (fig. 5F) and
reduced HU-induced NF (fig. 5G) were observed in both
WBS LBLs after transfection with RFC2 cDNA. Together,
these data provide strong evidence that haploinsufficiency
for RFC2 also confers an impaired ATR-dependent signal-
ing response.
Discussion
Here, we examined cell lines derived from patients with
BPES-ATR/, MDLS, and WBS, three distinct contiguous-
gene-deletion disorders that manifest microcephaly and
growth delay. In all cases, the heterozygous genomic de-
letions encompass a gene that is critical for the ATR-sig-
naling response—namely, ATR itself (BPES-ATR/), RPA1
(MDLS), or RFC2 (WBS). Patient-derived cell lines haplo-
insufficient for any of these genes displayed an impaired
response to DNA damage with use of assays that were
selected to identify defective ATR signaling. Indeed, the
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Figure 5. WBS cells, which show an impaired ATR-dependent DNA damage response. A, Chromosome 7 karyotype from WBS showing
the location of the submicroscopic heterozygous interstitial deletion on chromosome 7q11.23. B, Deletion mapping of patients with
WBS and SVAS showing the position of Elastin (ELN) and RFC2. The dashed line indicates the size of the heterozygous deletion. C,
Impaired HU-induced Chk1-pS317, seen in WBS LBLs (WBS-I and WBS-II) compared with those of the clinically normal parent (WT-I
and WT-II, respectively). Cells were treated with 500 mM HU for 1 h before extraction and were reprobed using a-Chk1 to confirm
loading. D, WBS LBLs, which exhibit impaired UV-induced G2/M checkpoint arrest. The MI was determined 24 h after UV irradiation (5
J/m2). WBS-I and WBS-II LBLs show defective UV-induced G2/M arrest, unlike WT LBLs from their parents (WT-I and WT-II, respectively).
E, Increased HU-induced NF, seen in WBS cell lines. LBLs were treated with HU (5 mM) and were examined for NF 24 h after treatment.
Both WBS-I and WBS-II LBLs show increased HU-induced NF, unlike WT LBLs from their parents (WT-I and WT-II, respectively). F, UV-
induced G2/M defect in WBS LBLs, complemented after transfection with RFC2 cDNA. WBS-I and WBS-II cells, either untransfected
(“UNT”) or transfected (“RFC2”) with pc-DNA3-RFC2, were UV irradiated (“UV”) (5 J/m2), and the MI was determined after 24 h. A
reduction in MI after UV irradiation is observed after transfection of WBS LBLs with RFC2 cDNA transfection (“RFC2 UV”) compared with
the untransfected irradiated cells (“UNT UV”). G, The increased HU-induced NF seen in WBS LBLs, complemented after transfection with
RFC2 cDNA. WBS-I and WBS-II, either untransfected (“UNT”) or transfected (“RFC2”) with pc-DNA3-RFC2, were treated with HU (5 mM)
24 h posttransfection. A reduction in HU-induced NF is seen after transfection of WBS LBLs with RFC2 cDNA (“RFC2 HU”), compared
with the untransfected HU-treated (“UNT HU”) cells.
defect was similar to that displayed by an SS cell line with
a homozygous, hypomorphic mutation in ATR (ATR-SS).3,6
Our findings therefore provide strong evidence that hap-
loinsufficiency for ATR, as well as additional components
of the ATR-dependent signaling pathway, confers an im-
paired ability to respond to DNA damage or replication-
fork stalling. Our assays were established to identify ATR-
signaling defects in SS and employ relatively modest DNA
damaging treatments, to allow the detection of potentially
hypomorphic mutations.3,6 Indeed, we observed that, after
more-dramatic treatments (e.g., high UV doses), the defect
in ATR-SS cells is overridden, presumably because of the
induction of a sufficient damage-response signal by the
residual protein.3 This is distinct from other DNA damage–
response assays, in which high doses are often used to
overload the pathway and expose a repair defect.35 Al-
though our assays are optimized to detect a subtle defi-
ciency and may not completely reflect the role of ATR
during development, they represent modest treatments
that may not be entirely distinct from those occurring
during cellular growth and development. Thus, the impact
of haploinsufficiency appears to represent a unique phe-
notype of ATR signaling, in contrast with other DNA dam-
age–response pathways.
Impaired ATR signaling is associated with microcephaly
and growth delay in humans.3,7,8,36 The correlation of the
presence of microcephaly and growth delay with impaired
ATR-pathway dysfunction in the haploinsufficiency dis-
orders presented here provides further evidence suggestive
of a causal relationship. Since ATR-SS is a recessive dis-
order, ATR haploinsufficiency alone is unlikely to confer
a clinical phenotype. Rather, the clinical features observed
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in these haploinsufficiency disorders are probably a con-
sequence of combined haploinsufficiency for ATR-signal-
ing genes and additional genes that may impact neuronal
development and cell proliferation. Indeed, combined het-
erozygosity of Lis1 and 14-3-3 has been shown to influ-
ence the severe clinical features of MDLS.37 Human brain
size has increased dramatically during evolution, requiring
enormous and rapid proliferation from a small number of
precursor stem cells.38 Moreover, developing neurons in-
cur high levels of oxidative DNA damage, placing a sig-
nificant load on the damage-response pathways. Thus, the
developing brain may have a high requirement for the
ATR-signaling pathway, necessitating a diploid content of
component proteins, particularly if further stress is im-
posed by haploinsufficiency of other genes. Mice, as mod-
els for haploinsufficiency disorders, have been used to in-
vestigate neuronal migration but may be limited in their
application concerning microcephaly because of the rel-
atively small size of murine brains compared with that of
human brains.39,40
Finally, it should be noted that, to our knowledge, de-
fective ATR-pathway function has not been described else-
where for any of the contiguous-gene-deletion disorders
investigated here (BPES-ATR/, MDLS, and WBS). Since
increased life expectancy due to improved medical super-
vision is now a feature of conditions such as MDLS, a
defective DNA damage response in this context may be
relevant to potential tumor development.41 Furthermore,
a defective DNA damage response can adversely affect treat-
ment of malignancy by standard chemotherapeutic or
bone marrow–transplantation regimens.42,43 It is unclear
whether any of the conditions investigated here are tu-
mor-predisposition conditions, although isolated reports
exist of malignancy in patients with MDLS and partic-
ularly WBS.41,44–46 Interestingly, hypomorphic mutations
in RFC subunits are associated with genetic instability
in yeast, and a heterozygous missense mutation in RPA1
results in increased levels of lymphoid malignancy in
mice.34,47,48 Defective ATR function has been described in
various cancer types.49–51 Furthermore, it has been sug-
gested that ATR may act as a tumor suppressor, when hap-
loinsufficient, under certain circumstances.52
A recent study reported that copy-number variation of
DNA sequences is a common genomic trait.53 Understand-
ing the impact of haploinsufficiency is likely to be impor-
tant for assessment of interindividual genetic variation, as
well as the basis underlying haploinsufficiency disorders.
In conclusion, we identify ATR signaling as a response
sensitive to haploinsufficiency at the cellular level, with
a provocative clinical link to microcephaly and growth
delay. This provides novel insight into the impact of ATR-
pathway haploinsufficiency and further strengthens the
link between defective ATR-pathway function and the de-
velopment of microcephaly and growth retardation in
humans.
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